<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">prmed</journal-id><journal-title-group><journal-title xml:lang="ru">Первичная медико-санитарная помощь</journal-title><trans-title-group xml:lang="en"><trans-title>Primary Health Care (Russian Federation)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-4123</issn><issn pub-type="epub">3034-4565</issn><publisher><publisher-name>LTD "Silicea-Poligraf"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/3034-4123-2026-148</article-id><article-id custom-type="edn" pub-id-type="custom">PECPZH</article-id><article-id custom-type="elpub" pub-id-type="custom">prmed-148</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Ведение пациентов с синдромом раздраженного кишечника в медицинских организациях, оказывающих первичную медико-санитарную помощь. Методические рекомендации</article-title><trans-title-group xml:lang="en"><trans-title>Management of patients with irritable bowel syndrome in primary care. Guidelines</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна (Oksana M. Drapkina) — д.м.н., профессор, академик РАН, директор; главный внештатный специалист по терапии и общей врачебной практике Минздрава России; зав. кафедрой терапии и профилактической медицины</p><p>Петроверигский пер., 10, стр. 3, Москва, 101990;</p><p>ул. Долгоруковская, д. 4, Москва, 127006</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990;</p><p>Dolgorukovskaya str., 4, Moscow, 127006</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6114-564X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маев</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maev</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Маев Игорь Вениаминович (Igor V. Maev) — д.м.н., профессор, академик РАН, проректор по учебной работе — первый проректор, зав. кафедрой пропедевтики внутренних болезней и гастроэнтерологии, вице-президент РОПНИЗ по направлению "Гастроэнтерология"</p><p>ул. Долгоруковская, д. 4, Москва, 127006</p></bio><bio xml:lang="en"><p>Dolgorukovskaya str., 4, Moscow, 127006</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6581-7017</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ливзан</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Livzan</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ливзан Мария Анатольевна (Maria A. Livzan) — д.м.н., профессор, чл.-корр. РАН, главный внештатный специалист по терапии Сибирского федерального округа, вице-президент РОПНИЗ по направлению "Гастроэнтерология"</p><p>ул. Ленина, д. 12, Омск, 644099</p></bio><bio xml:lang="en"><p>Lenin str., 12, Omsk, 644099</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8984-9056</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шепель</surname><given-names>Р. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shepel</surname><given-names>R. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шепель Руслан Николаевич (Ruslan N. Shepel) — к.м.н., зам. директора по перспективному развитию медицинской деятельности, главный внештатный специалист по терапии Минздрава России в Центральном федеральном округе, исполнительный директор РОПНИЗ</p><p>Петроверигский пер., 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9370-4768</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаус</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gaus</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гаус Ольга Владимировна (Olga V. Gaus) — д.м.н., профессор кафедры факультетской терапии и гастроэнтерологии</p><p>ул. Ленина, д. 12, Омск, 644099</p></bio><bio xml:lang="en"><p>Lenin str., 12, Omsk, 644099</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8325-5927</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жарова</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Zharova</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жарова Мария Евгеньевна (Mariia E. Zharova) — к.м.н., врач-терапевт, врач-гастроэнтеролог, эксперт центра организации программ скрининга онкологических заболеваний, с.н.с. отдела научно-стратегического развития первичной медико-санитарной помощи</p><p>Петроверигский пер., 10, стр. 3, Москва, 101990</p></bio><bio xml:lang="en"><p>Petroverigsky Lane, 10, bld. 3, Moscow, 101990</p></bio><email xlink:type="simple">m.e.zharova@ropniz.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0982-2006</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черемушкин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheremushkin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черемушкин Сергей Викторович (Sergey V. Cheremushkin) — к.м.н., доцент кафедры пропедевтики внутренних болезней и гастроэнтерологии</p><p>ул. Долгоруковская, д. 4, Москва, 127006</p></bio><bio xml:lang="en"><p>Dolgorukovskaya str., 4, Moscow, 127006</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России; ФГБОУ ВО "Российский университет медицины" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine; Russian University of Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО "Российский университет медицины" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian University of Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО "Омский государственный медицинский университет" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Omsk State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>16</day><month>07</month><year>2026</year></pub-date><volume>3</volume><issue>2S</issue><issue-title>Рекомендации по диспансерному наблюдению</issue-title><fpage>269</fpage><lpage>294</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Драпкина О.М., Маев И.В., Ливзан М.А., Шепель Р.Н., Гаус О.В., Жарова М.Е., Черемушкин С.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Драпкина О.М., Маев И.В., Ливзан М.А., Шепель Р.Н., Гаус О.В., Жарова М.Е., Черемушкин С.В.</copyright-holder><copyright-holder xml:lang="en">Drapkina O.M., Maev I.V., Livzan M.A., Shepel R.N., Gaus O.V., Zharova M.E., Cheremushkin S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://prmed.elpub.ru/jour/article/view/148">https://prmed.elpub.ru/jour/article/view/148</self-uri><abstract><p>Синдром раздраженного кишечника (СРК) является одним из наиболее распространенных функциональных расстройств желудочно-кишечного тракта и характеризуется хроническим рецидивирующим течением, абдоминальной болью, нарушением частоты и формы стула, метеоризмом и значимым влиянием на качество жизни пациентов. СРК ассоциирован со снижением трудоспособности, частыми обращениями за медицинской помощью, затратами на диагностику и лечение, а также необходимостью длительного динамического наблюдения. Актуальность разработки методических рекомендаций обусловлена потребностью в унификации подходов к ведению пациентов с СРК на амбулаторном этапе, повышении эффективности терапии, своевременном исключении органической патологии и обеспечении преемственности между врачами-терапевтами, гастроэнтерологами и другими специалистами.</p><p>Методические рекомендации посвящены ведению взрослых пациентов с СРК в медицинских организациях, оказывающих первичную медико-санитарную помощь. В документе представлены критерии установления диагноза, включая Римские критерии IV и V пересмотров, алгоритм динамического наблюдения, перечень "симптомов тревоги", подходы к лабораторной и инструментальной диагностике, оценке тяжести заболевания, формулировке диагноза, определению показаний к госпитализации и направлению к врачам-специалистам. Отдельное внимание уделено немедикаментозной и медикаментозной терапии, профилактическому консультированию, оценке приверженности лечению, информированию пациента и оформлению медицинской документации.</p><p>Методические рекомендации предназначены для врачей-терапевтов, врачей общей практики, гастроэнтерологов, специалистов медицинских организаций первичного звена, а также организаторов здравоохранения, участвующих в маршрутизации и динамическом наблюдении пациентов с СРК.</p></abstract><trans-abstract xml:lang="en"><p>Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders characterized by chronic recurrent symptoms, abdominal pain, irregular stool frequency and consistency, flatulence, and a significant impact on patients' quality of life. IBS is associated with decreased productivity, frequent health encounters, diagnostic and treatment costs, and the need for long-term follow-up. The development of guidelines is relevant to the need to standardize approaches to outpatient management of IBS patients, improve treatment effectiveness, promptly rule out organic pathology, and ensure continuity of care between general practitioners, gastroenterologists, and other specialists.</p><p>These guidelines address the management of adult patients with IBS in primary care. The document presents diagnostic criteria, including the Rome IV and V criteria, a dynamic monitoring algorithm, a list of alarm symptoms, approaches to laboratory and imaging diagnostics, disease severity assessment, diagnosis formulation, determining indications for hospitalization, and referral to specialist physicians. Particular attention is paid to non-drug and drug therapy, preventive counseling, assessing treatment adherence, informing the patient, and preparing medical documentation.</p><p>These guidelines are intended for internists, general practitioners, gastroenterologists, primary care specialists, and healthcare providers involved in the management and dynamic monitoring of patients with IBS.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром раздраженного кишечника</kwd><kwd>первичная медико-санитарная помощь</kwd><kwd>функциональные заболевания кишечника</kwd><kwd>абдоминальная боль</kwd><kwd>Римские критерии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>irritable bowel syndrome</kwd><kwd>primary care</kwd><kwd>functional bowel disorders</kwd><kwd>abdominal pain</kwd><kwd>Rome criteria</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arif TB, Ali SH, Bhojwani KD, et al. Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis. Eur J Gastroenterol Hepatol. 2025;37(12):1314-25. doi:10.1097/MEG.0000000000002994.</mixed-citation><mixed-citation xml:lang="en">Arif TB, Ali SH, Bhojwani KD, et al. Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis. Eur J Gastroenterol Hepatol. 2025;37(12):1314-25. doi:10.1097/MEG.0000000000002994.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. doi:10.1053/j.gastro.2020.04.014.</mixed-citation><mixed-citation xml:lang="en">Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3. doi:10.1053/j.gastro.2020.04.014.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wu X, Wang J, Ye Z, et al. Risk of Colorectal Cancer in Patients With Irritable Bowel Syndrome: A Meta-Analysis of Population-Based Observational Studies. Front Med (Lausanne). 2022;9:819122. doi:10.3389/fmed.2022.819122.</mixed-citation><mixed-citation xml:lang="en">Wu X, Wang J, Ye Z, et al. Risk of Colorectal Cancer in Patients With Irritable Bowel Syndrome: A Meta-Analysis of Population-Based Observational Studies. Front Med (Lausanne). 2022;9:819122. doi:10.3389/fmed.2022.819122.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Staudacher HM, Black CJ, Teasdale SB, et al. Irritable bowel syndrome and mental health comorbidity - approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol. 2023;20(9):582-96. doi:10.1038/s41575-023-00794-z.</mixed-citation><mixed-citation xml:lang="en">Staudacher HM, Black CJ, Teasdale SB, et al. Irritable bowel syndrome and mental health comorbidity - approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol. 2023;20(9):582-96. doi:10.1038/s41575-023-00794-z.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. doi:10.5056/jnm16214.</mixed-citation><mixed-citation xml:lang="en">Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. doi:10.5056/jnm16214.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Drossman DA, Chang L, Tack J. Disorders of Gut-Brain Interaction and the Rome V Process. Gastroenterology. 2026;170(6):1083-98. doi:10.1053/j.gastro.2026.02.014.</mixed-citation><mixed-citation xml:lang="en">Drossman DA, Chang L, Tack J. Disorders of Gut-Brain Interaction and the Rome V Process. Gastroenterology. 2026;170(6):1083-98. doi:10.1053/j.gastro.2026.02.014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Махов В.М., Ромасенко Л.В., Турко Т.В., Шептак Н.Н. Синдром раздраженного кишечника: коморбидное соматопсихическое заболевание. Доказательная гастроэнтерология. 2014;3(2):56-61. EDN: SXTOWD.</mixed-citation><mixed-citation xml:lang="en">Makhov VM, Romasenko LV, Turko TV, Sheptak NN. Irritated bowel syndrome is a co-morbid somatopsychic condition. Russian Journal of Evidence-Based Gastroenterology. 2014;3(2):56-61. (In Russ.) EDN: SXTOWD.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Казюлин А.Н., Гончаренко А.Ю., Павлеева Е.Е. и др. Общность и различия между синдромом раздраженного кишечника и заболеваниями, протекающими с СРК-подобными симптомами. Доказательная гастроэнтерология. 2024;13(1):66-78. doi:10.17116/dokgastro20241301166.</mixed-citation><mixed-citation xml:lang="en">Kazyulin AN, Goncharenko AYu, Pavleeva EE, et al. Understanding similarities and differences of irritable bowel syndrome and conditions with IBS-like symptoms. Russian Journal of Evidence-Based Gastroenterology. 2024;13(1):66-78. (In Russ.) doi:10.17116/dokgastro20241301166.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Федорин М.М., Ливзан М.А., Гаус О.В. Синдром раздраженного кишечника у лиц с избыточной массой тела и ожирением: новый фенотип заболевания? Доказательная гастроэнтерология. 2021;10(2):52-60. doi:10.17116/dokgastro20211002152.</mixed-citation><mixed-citation xml:lang="en">Fedorin MM, Livzan MA, Gaus OV. IBS in overweight and obese individuals: a new disease phenotype? Russian Journal of Evidence-Based Gastroenterology. 2021;10(2):52-60. (In Russ.) doi:10.17116/dokgastro20211002152.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. doi:10.1046/j.1365-2036.1997.142318000.x.</mixed-citation><mixed-citation xml:lang="en">Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. doi:10.1046/j.1365-2036.1997.142318000.x.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Algera J, Colomier E, Simrén M. The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence. Nutrients. 2019;11(9):2162. doi:10.3390/nu11092162.</mixed-citation><mixed-citation xml:lang="en">Algera J, Colomier E, Simrén M. The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence. Nutrients. 2019;11(9):2162. doi:10.3390/nu11092162.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi:10.3390/nu11081824.</mixed-citation><mixed-citation xml:lang="en">El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi:10.3390/nu11081824.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Melchior C, Algera J, Colomier E, et al. Irritable bowel syndrome with foodrelated symptoms: Future directions in the clinical management. United European Gastroenterol J. 2022;10(6):594-600. doi:10.1002/ueg2.12265.</mixed-citation><mixed-citation xml:lang="en">Melchior C, Algera J, Colomier E, et al. Irritable bowel syndrome with foodrelated symptoms: Future directions in the clinical management. United European Gastroenterol J. 2022;10(6):594-600. doi:10.1002/ueg2.12265.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Гаус О.В., Ливзан М.А., Попелло Д.В. Управление питанием при синдроме раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2020;(10):112-22. doi:10.31146/1682-8658-ecg-182-10-112-122. EDN: MJUSRH.</mixed-citation><mixed-citation xml:lang="en">Gaus OV, Livzan MA, Popello DV. Power management for irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2020;(10):112-22. (In Russ.) doi:10.31146/1682-8658-ecg-182-10-112-122. EDN: MJUSRH.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036.</mixed-citation><mixed-citation xml:lang="en">Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Paduano D, Cingolani A, Tanda E, Usai P.Effect of Three Diets (Low-FODMAP, Gluten-free and Balanced) on Irritable Bowel Syndrome Symptoms and HealthRelated Quality of Life. Nutrients. 2019;11(7):1566. doi:10.3390/nu11071566.</mixed-citation><mixed-citation xml:lang="en">Paduano D, Cingolani A, Tanda E, Usai P.Effect of Three Diets (Low-FODMAP, Gluten-free and Balanced) on Irritable Bowel Syndrome Symptoms and HealthRelated Quality of Life. Nutrients. 2019;11(7):1566. doi:10.3390/nu11071566.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. doi:10.1136/gutjnl-2021-324598.</mixed-citation><mixed-citation xml:lang="en">Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. doi:10.1136/gutjnl-2021-324598.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Frieling T, Heise J, Krummen B, et al. Tolerability of FODMAP — reduced diet in irritable bowel syndrome — efficacy, adherence, and body weight course. Z Gastroenterol. 2019;57(6):740-4. English. doi:10.1055/a-0859-7531.</mixed-citation><mixed-citation xml:lang="en">Frieling T, Heise J, Krummen B, et al. Tolerability of FODMAP — reduced diet in irritable bowel syndrome — efficacy, adherence, and body weight course. Z Gastroenterol. 2019;57(6):740-4. English. doi:10.1055/a-0859-7531.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gravina AG, Dallio M, Romeo M, et al. Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. Nutrients. 2020;12(4):928. doi:10.3390/nu12040928.</mixed-citation><mixed-citation xml:lang="en">Gravina AG, Dallio M, Romeo M, et al. Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. Nutrients. 2020;12(4):928. doi:10.3390/nu12040928.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Quigley EM, Fried M, Gwee KA, et al.; Review Team:. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50(9):704-13. doi:10.1097/MCG.0000000000000653.</mixed-citation><mixed-citation xml:lang="en">Quigley EM, Fried M, Gwee KA, et al.; Review Team:. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J Clin Gastroenterol. 2016;50(9):704-13. doi:10.1097/MCG.0000000000000653.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Маев И.В., Шептулин А.А. и др. Резолюция Экспертного совета "Как улучшить результаты лечения больных с функциональной диспепсией и синдромом раздраженного кишечника"? Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):101-4. doi:10.22416/1382-4376-2016-26-2-101-104.</mixed-citation><mixed-citation xml:lang="en">Ivashkin VT, Mayev IV, Sheptulin AA, et al. The resolution of Advisory council "How to improve treatment results functional dyspepsia and irritable bowel syndrome"? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):101-4. (In Russ.) doi:10.22416/1382-4376-2016-26-2-101-104.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Гаус О.В., Ливзан М.А. Фенотипы синдрома раздраженного кишечника: ведущие факторы генетики и эпигенетики, механизмы формирования. Терапевтический архив. 2023;95(2):164-72. doi:10.26442/00403660.2023.02.202111.</mixed-citation><mixed-citation xml:lang="en">Gaus OV, Livzan MA. Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(2):164-72. (In Russ.) doi:10.26442/00403660.2023.02.202111.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ильченко А.А. Эффективность мебеверина гидрохлорида при билиарной патологии. РМЖ. 2003;(4):206.</mixed-citation><mixed-citation xml:lang="en">Ilchenko AA. The effectiveness of mebeverine hydrochloride in biliary pathology. RMJ. 2003;(4):206. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Den Hertog A, Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353-5. doi:10.1016/0014-2999(87)90594-2.</mixed-citation><mixed-citation xml:lang="en">Den Hertog A, Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353-5. doi:10.1016/0014-2999(87)90594-2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Abdel-Hamid SM, Abdel-Hady SE, El-Shamy AA, El-Dessouky HF. Formulation of an antispasmodic drug as a topical local anesthetic. Int J Pharm. 2006;326(1-2):107-18. doi:10.1016/j.ijpharm.2006.07.028.</mixed-citation><mixed-citation xml:lang="en">Abdel-Hamid SM, Abdel-Hady SE, El-Shamy AA, El-Dessouky HF. Formulation of an antispasmodic drug as a topical local anesthetic. Int J Pharm. 2006;326(1-2):107-18. doi:10.1016/j.ijpharm.2006.07.028.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lindner A, Selzer H, Claassen V, et al. Pharmacological Properties Of Mebeverine, A Smooth-Muscle Relaxant. Arch Int Pharmacodyn Ther. 1963;145:378-95.</mixed-citation><mixed-citation xml:lang="en">Lindner A, Selzer H, Claassen V, et al. Pharmacological Properties Of Mebeverine, A Smooth-Muscle Relaxant. Arch Int Pharmacodyn Ther. 1963;145:378-95.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. doi:10.1046/j.1365-2036.2001.00937.x.</mixed-citation><mixed-citation xml:lang="en">Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. doi:10.1046/j.1365-2036.2001.00937.x.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Boisson J., Coudert P., Depuis J. Long term tolerance of mebeverine in French // Med Chir Digest. 1987;16(289):92-5.</mixed-citation><mixed-citation xml:lang="en">Boisson J., Coudert P., Depuis J. Long term tolerance of mebeverine in French // Med Chir Digest. 1987;16(289):92-5.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210-58. doi:10.2165/00003088-199732030-00004.</mixed-citation><mixed-citation xml:lang="en">Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210-58. doi:10.2165/00003088-199732030-00004.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41. doi:10.1016/j.pharmthera.2012.12.007.</mixed-citation><mixed-citation xml:lang="en">Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41. doi:10.1016/j.pharmthera.2012.12.007.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Агафонова Н.А. и др. Абдоминальные боли: механизмы формирования, рациональный подход к выбору терапии. РМЖ. Болезни органов пищеварения. 2011;(2):47-9.</mixed-citation><mixed-citation xml:lang="en">Yakovenko EP, Yakovenko AV, Agafonova NA, et al. Abdominal pain: mechanisms of formation, rational approach to the choice of therapy. breast cancer. Diseases of the digestive system. 2011;(2):47-9. (In Russ.) Яковенко Э.П., Яковенко А.В.,</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225-46. doi:10.1177/030006059702500501.</mixed-citation><mixed-citation xml:lang="en">Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225-46. doi:10.1177/030006059702500501.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong YQ, Zhu J, Guo JN, et al. [A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrheadominant irritable bowel syndrome]. Zhonghua Nei Ke Za Zhi. 2007;46(11):899-902. Chinese.</mixed-citation><mixed-citation xml:lang="en">Zhong YQ, Zhu J, Guo JN, et al. [A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrheadominant irritable bowel syndrome]. Zhonghua Nei Ke Za Zhi. 2007;46(11):899-902. Chinese.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kovaleva A, Poluektova E, Maslennikov R, et al. Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial. J Clin Med. 2023;12(18):6064. doi:10.3390/jcm12186064.</mixed-citation><mixed-citation xml:lang="en">Kovaleva A, Poluektova E, Maslennikov R, et al. Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial. J Clin Med. 2023;12(18):6064. doi:10.3390/jcm12186064.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко М.Е., Туркина С.В., Тыщенко И.А. и др. Оценка эффективности ребамипида в лечении функциональной диспепсии и синдрома раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2022;(9):74-81. doi:10.31146/1682-8658-ecg-205-9-74-81.</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Turkina SV, Tyshchenko IA, et al. Evaluation of the effi cacy of rebamipide in functional dyspepsia and irritable bowel syndrome treatment. Experimental and Clinical Gastroenterology. 2022;(9):74-81. (In Russ.) doi:10.31146/1682-8658-ecg-205-9-74-81.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Драпкина О.М. Разработка и валидизация новых опросников в медицине на примере шкалы приверженности лекарственной терапии. Рациональная Фармакотерапия в Кардиологии. 2021;17(4):576-83. doi:10.20996/1819-6446-2021-08-02.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. The Questionnaire Survey Method in Medicine on the Example of Treatment Adherence Scales. Rational Pharmacotherapy in Cardiology. 2021;17(4):576-83. (In Russ.) doi:10.20996/1819-6446-2021-08-02.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
